{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280196","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.490024+00:00","generated_at":"2026-05-16T20:30:00.953410+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data","bullets":["Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.","R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).","ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.","Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).","Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280196","json":"https://secwatch.observer/filing/0001193125-25-280196.json","markdown":"https://secwatch.observer/filing/0001193125-25-280196.md","text":"https://secwatch.observer/filing/0001193125-25-280196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/0001193125-25-280196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/oric-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:30:00.953410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}